JP5701606B2 - ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 - Google Patents

ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 Download PDF

Info

Publication number
JP5701606B2
JP5701606B2 JP2010532344A JP2010532344A JP5701606B2 JP 5701606 B2 JP5701606 B2 JP 5701606B2 JP 2010532344 A JP2010532344 A JP 2010532344A JP 2010532344 A JP2010532344 A JP 2010532344A JP 5701606 B2 JP5701606 B2 JP 5701606B2
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010532344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503014A (ja
JP2011503014A5 (enExample
Inventor
ティボアー ケラー，
ティボアー ケラー，
リーツェン ヒ，
リーツェン ヒ，
ベンキー ラマクリシュナ，
ベンキー ラマクリシュナ，
ローラ エー． ビテール，
ローラ エー． ビテール，
Original Assignee
セルデックス セラピューティクス インコーポレイテッド
セルデックス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40257038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5701606(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セルデックス セラピューティクス インコーポレイテッド, セルデックス セラピューティクス インコーポレイテッド filed Critical セルデックス セラピューティクス インコーポレイテッド
Publication of JP2011503014A publication Critical patent/JP2011503014A/ja
Publication of JP2011503014A5 publication Critical patent/JP2011503014A5/ja
Application granted granted Critical
Publication of JP5701606B2 publication Critical patent/JP5701606B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
JP2010532344A 2007-11-07 2008-11-07 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 Expired - Fee Related JP5701606B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US225307P 2007-11-07 2007-11-07
US61/002,253 2007-11-07
US19155108P 2008-09-10 2008-09-10
US61/191,551 2008-09-10
PCT/US2008/082745 WO2009061996A2 (en) 2007-11-07 2008-11-07 Antibodies that bind human dendritic and epithelial cell 205 (dec-205)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014255753A Division JP6067667B2 (ja) 2007-11-07 2014-12-18 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体

Publications (3)

Publication Number Publication Date
JP2011503014A JP2011503014A (ja) 2011-01-27
JP2011503014A5 JP2011503014A5 (enExample) 2014-03-20
JP5701606B2 true JP5701606B2 (ja) 2015-04-15

Family

ID=40257038

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010532344A Expired - Fee Related JP5701606B2 (ja) 2007-11-07 2008-11-07 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体
JP2014255753A Expired - Fee Related JP6067667B2 (ja) 2007-11-07 2014-12-18 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体
JP2016137221A Pending JP2017014218A (ja) 2007-11-07 2016-07-12 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014255753A Expired - Fee Related JP6067667B2 (ja) 2007-11-07 2014-12-18 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体
JP2016137221A Pending JP2017014218A (ja) 2007-11-07 2016-07-12 ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体

Country Status (17)

Country Link
US (4) US8236318B2 (enExample)
EP (2) EP2224954B1 (enExample)
JP (3) JP5701606B2 (enExample)
KR (2) KR101811965B1 (enExample)
CN (1) CN101888856B (enExample)
AU (1) AU2008323848B2 (enExample)
BR (1) BRPI0820270A2 (enExample)
CA (1) CA2704583A1 (enExample)
DK (1) DK2224954T3 (enExample)
EA (2) EA026990B1 (enExample)
ES (1) ES2445755T3 (enExample)
IL (1) IL205393A (enExample)
MX (1) MX2010005022A (enExample)
NZ (2) NZ585556A (enExample)
SG (2) SG187482A1 (enExample)
WO (1) WO2009061996A2 (enExample)
ZA (1) ZA201003101B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641927B1 (en) * 2003-02-18 2015-07-08 Baylor College of Medicine Induced activation in dendritic cells
JP5285278B2 (ja) 2004-12-22 2013-09-11 クリーブランド クリニック ファウンデイション フラゲリン関連ポリペプチドおよびその使用
WO2008049113A2 (en) * 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
NZ578696A (en) * 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
JP5577337B2 (ja) 2008-08-01 2014-08-20 クリーブランド バイオラブス， インコーポレイテッド 再灌流傷害を治療するための方法
ES2633470T3 (es) * 2008-09-22 2017-09-21 Baylor College Of Medicine Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
AU2010291939B2 (en) 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
CA2813494A1 (en) * 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
CA2781248A1 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
AU2011239706B2 (en) 2010-04-13 2015-08-20 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
CA2795947A1 (en) * 2010-04-16 2011-10-20 Bellicum Pharmaceuticals, Inc. Method for treating solid tumors
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
DE102010039019B4 (de) 2010-08-06 2014-08-07 Technische Universität Dresden Antikörper gegen 6-sulfo LacNAc positive humane dendritische Zellen und deren Verwendung
RU2013110889A (ru) * 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11291483B2 (en) 2010-10-20 2022-04-05 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US11484627B2 (en) 2010-10-20 2022-11-01 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
WO2015095745A1 (en) 2010-10-20 2015-06-25 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
EP2663580B1 (en) * 2011-01-10 2016-12-07 CT Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
JP6041444B2 (ja) 2011-01-10 2016-12-07 クリーブランド バイオラブズ，インコーポレイテッド 癌を治療するためのＴｏｌｌ様受容体アゴニストの使用
WO2013009841A1 (en) * 2011-07-11 2013-01-17 Baylor Research Institute Subsets of antigen-presenting cells (apc's) in the human vagina and their distinct functions
KR20140054140A (ko) * 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
SI2831113T1 (en) * 2012-03-28 2018-08-31 Sanofi Antibodies to bradykinin b1 receptor ligands
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
CN103044552B (zh) * 2012-12-11 2019-01-29 中国医学科学院病原生物学研究所 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
SG11201506974XA (en) 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
DK3004329T3 (da) 2013-06-05 2020-05-18 Bellicum Pharmaceuticals Inc Fremgangsmåder til induktion af delvis apoptose under anvendelse af caspasepolypeptider
MX346878B (es) 2013-06-26 2017-03-28 Univ Nac Autónoma De México Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
US10081682B2 (en) * 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
CN111849912B (zh) 2014-02-14 2024-03-15 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
JP6940916B2 (ja) 2014-07-30 2021-09-29 ゲノム プロテクション，インコーポレイテッド フラジェリン組成物および使用
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
CN107056932B (zh) * 2016-12-24 2021-04-09 深圳大学 一种氨基酸序列、含ova表位的融合蛋白及其制备方法和应用
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
MD3691692T2 (ro) * 2017-10-14 2021-05-31 Abbvie Inc Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora
WO2019082208A1 (en) * 2017-10-27 2019-05-02 Indian Institute Of Science Dendritic cells-targeting vaccine
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
JPWO2019244973A1 (ja) * 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
JP7396275B2 (ja) 2018-06-29 2023-12-12 日本ゼオン株式会社 識別媒体、真正性判定方法、及び物品
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
WO2020119728A1 (zh) * 2018-12-12 2020-06-18 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
WO2021108637A1 (en) * 2019-11-26 2021-06-03 Cedars-Sinai Medical Center Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
CA3160584A1 (en) * 2019-12-05 2021-06-10 Georgina Jane Clark Antigen loading
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
AU2022282609A1 (en) 2021-05-26 2023-11-30 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
CN115028741A (zh) * 2022-06-21 2022-09-09 苏州工业园区唯可达生物科技有限公司 一种肿瘤抗原抗体复合物及制备方法和应用
CN114949191A (zh) * 2022-06-21 2022-08-30 苏州工业园区唯可达生物科技有限公司 一种肿瘤疫苗及其制备方法
CN114887047A (zh) * 2022-06-21 2022-08-12 苏州工业园区唯可达生物科技有限公司 基于ny-eso-1肿瘤抗原的疫苗及制备方法
CN114989311A (zh) * 2022-06-21 2022-09-02 苏州工业园区唯可达生物科技有限公司 3g9-lnm抗体偶联蛋白及其制备方法和应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857090A (en) * 1955-06-02 1958-10-21 Crown Zellerbach Corp Container for heavy articles
US2887389A (en) * 1955-06-03 1959-05-19 Creath Q Linville Cartons
US3164316A (en) * 1962-05-21 1965-01-05 Weyerhaeuser Co Carton
US3353740A (en) * 1965-12-28 1967-11-21 Int Paper Co Reclosable carton
US3447735A (en) * 1967-07-03 1969-06-03 Western Kraft Corp Easy-opening container
US3552633A (en) * 1969-10-27 1971-01-05 Inland Container Corp Pallet case
US3698548A (en) * 1970-06-15 1972-10-17 Robert N Stenzel Box for dispensing flexible sheet material
US3883067A (en) * 1972-12-15 1975-05-13 Continental Can Co Carton corner construction
US4267959A (en) * 1979-10-22 1981-05-19 Westvaco Corporation Hinged paperboard container
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3886363T3 (de) 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
SG46445A1 (en) * 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095729A1 (en) 1990-11-06 1992-05-07 Raymond A. B. Ezekowitz Soluble mannose receptor peptides
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
GB9117522D0 (en) 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5876917A (en) * 1993-11-04 1999-03-02 Canterbury Health Limited Dendritic cell-specific antibodies and method for their preparation
WO1995015340A1 (en) 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
US5541110A (en) * 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
EP0808366A1 (en) 1995-01-31 1997-11-26 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
JP2000512490A (ja) * 1996-05-29 2000-09-26 デレク ナイジェル ジョン ハート 樹状細胞のレセプター
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6069233A (en) 1996-10-03 2000-05-30 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6479247B1 (en) * 1996-10-09 2002-11-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
CN1493597A (zh) * 1997-07-09 2004-05-05 ���鹫˾ 分离树突状细胞膜蛋白基因
ES2322212T3 (es) 1997-09-29 2009-06-17 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Composicion de antigeno y linea celular que lleva el receptor manosa.
US6340569B1 (en) * 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2323083A1 (en) 1998-03-17 1999-09-23 Schering Corporation Isolated mammalian membrane protein genes and related reagents
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
AU4039999A (en) 1998-05-11 1999-11-29 Micromet Ag Antibodies to dendritic cells and human dendritic cell populations and uses thereof
WO2000000156A2 (en) 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
KR100295558B1 (ko) 1998-06-27 2001-07-12 김기태 1차면역세포들중덴드리틱세포(dendriticcell)표면에특이하게작용하는단클론항체3-6-a
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
NZ513254A (en) * 1999-02-18 2003-10-31 F Thioamide derivatives
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6774226B1 (en) 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU2001255326B2 (en) * 2000-04-12 2005-12-15 University Of Rochester Targeted vaccine delivery systems
US7201714B2 (en) * 2000-04-27 2007-04-10 Graphic Packaging International, Inc. Paperboard cartons with laminated reinforcing ribbons and method of printing same
DK1282646T3 (da) 2000-05-08 2012-05-14 Celldex Res Corp Humane monoklonale antistoffer mod dendritiske celler
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
CA2468878A1 (en) * 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7541032B2 (en) 2002-09-20 2009-06-02 Stichting Katholieke Universiteit Antigen uptake receptor for Candida albicans on dendritic cells
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US9243064B2 (en) * 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
KR20050114224A (ko) * 2003-03-04 2005-12-05 알렉시온 파마슈티칼스, 인코포레이티드 항원 제공 세포의 내성을 유도함으로써 자가 면역 질환치료 방법
US6834793B2 (en) * 2003-05-31 2004-12-28 Graphic Packaging International, Inc. Enclosed container carton convertible into a tray
WO2005018610A1 (en) 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
US7579187B2 (en) * 2004-09-06 2009-08-25 Kyoma Hakko Kirin Co., Ltd. Anti-A33 antibody
CA2623406C (en) * 2005-09-21 2011-11-15 Graphic Packaging International, Inc. Reinforced cartons
CN101360761B (zh) * 2005-12-08 2012-09-12 米德列斯公司 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
SG170080A1 (en) * 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
KR102264548B1 (ko) 2014-11-21 2021-06-16 삼성전자주식회사 반도체 패키지 및 그 제조 방법

Also Published As

Publication number Publication date
JP2017014218A (ja) 2017-01-19
AU2008323848A1 (en) 2009-05-14
US8362214B2 (en) 2013-01-29
US20100098704A1 (en) 2010-04-22
EP2224954B1 (en) 2014-01-08
JP2011503014A (ja) 2011-01-27
NZ599777A (en) 2013-09-27
US20130101593A1 (en) 2013-04-25
HK1146898A1 (en) 2011-07-22
BRPI0820270A2 (pt) 2015-06-16
EP2570137A3 (en) 2013-08-21
KR20100100857A (ko) 2010-09-15
EA201000770A1 (ru) 2010-12-30
JP2015083010A (ja) 2015-04-30
US20120309031A1 (en) 2012-12-06
US9624300B2 (en) 2017-04-18
KR101624751B1 (ko) 2016-05-27
SG10201605208QA (en) 2016-08-30
EA026990B1 (ru) 2017-06-30
KR101811965B1 (ko) 2017-12-22
US20090175880A1 (en) 2009-07-09
ES2445755T3 (es) 2014-03-05
ZA201003101B (en) 2014-10-29
CA2704583A1 (en) 2009-05-14
KR20160017128A (ko) 2016-02-15
DK2224954T3 (en) 2014-03-03
US8236318B2 (en) 2012-08-07
IL205393A (en) 2015-04-30
WO2009061996A2 (en) 2009-05-14
WO2009061996A3 (en) 2009-09-03
NZ585556A (en) 2012-07-27
AU2008323848B2 (en) 2014-09-25
EP2570137A2 (en) 2013-03-20
MX2010005022A (es) 2010-06-02
IL205393A0 (en) 2010-12-30
JP6067667B2 (ja) 2017-01-25
CN101888856B (zh) 2014-08-27
CN101888856A (zh) 2010-11-17
SG187482A1 (en) 2013-02-28
EP2224954A2 (en) 2010-09-08
EA201692127A1 (ru) 2017-08-31
US8586720B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
JP6067667B2 (ja) ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体
JP6486300B2 (ja) ヒトｃｄ２７に結合する抗体およびその使用
CN116059351A (zh) 结合人cd40的激动性抗体及其用途
AU2018201621A1 (en) Antibodies that bind human CD27 and uses thereof
AU2013201417B2 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
AU2013203270B2 (en) Antibodies that bind human CD27 and uses thereof
HK1183235A (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
HK1146898B (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130729

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20131011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131108

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150218

R150 Certificate of patent or registration of utility model

Ref document number: 5701606

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees